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HEPCIDIN AS A POSSIBLE MARKER IN DETERMINATION 
OF MALIGNANCY DEGREE AND SENSITIVITY OF BREAST CANCER 
CELLS TO CYTOSTATIC DRUGS
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Aim: To investigate the role of hepcidin (Hepc) in the formation of cells malignant phenotype in vitro and its expression in the dyna mics 
of growth of Walker-256 carcinosarcoma with different sensitivity to doxorubicin (Dox). Materials and Methods: The cell lines used 
in the analysis included T47D, MCF-7, MDA-MB-231, MDA-MB-468, MCF/CP, and MCF/Dox. Hepc expression was studied 
by immunocytochemical method. “Free” iron content was determined by EPR spectroscopy. Determination of Hepc expression 
in homogenates of tumor tissue and in blood serum of rats with Dox-sensitive and -resistant Walker-256 carcinosarcoma was per-
formed. Results: It was found that Hepc levels in breast cancer (BC) cells with high degree of malignancy (MDA-MB-231, MDA-
MB-468) and drug-resistant phenotype (MCF/CP, MCF/Dox) were by 1.5–2 times higher (p < 0.05) in comparison with sensitive 
and less malignant BC cells. The development of drug-resistant phenotype in Walker-256 carcinosarcoma cells was accompanied 
by increasing of Hepc and “free” iron content (by 2.4 and 1.2 times, respectively). Conclusion: The data of in vitro and in vivo research 
evidenced on involvement of Hepc in formation of BC cells malignant phenotype and their resistance to Dox.
Key Words: breast cancer, hepcidin, “free” iron, doxorubicin, Walker-256 carcinosarcoma, proliferative activity, invasive potential, 
adhesion molecules.
Breast cancer (BC) is one of the most common 
malignancies among the women both in Ukraine and 
worldwide. Despite the new diagnostic aids and more 
effective treatment methods, the results of BC treat-
ment remain unsatisfactory. This is due to genetic and 
morphological heterogeneity of tumors, which is based 
on the degree of malignancy of tumor cells. According 
to some studies, the degree of malignancy is a key 
factor that reflects biological features of tumors. 
It is proved that increase of the degree of malignancy 
correlates with the development of metastases, sen-
sitivity to chemo- and hormonal therapy and affects 
treatment selection, risk of relapses and the quality 
of life among patients with BC [1, 2]. Hence, currently 
there is a need in search for additional informative 
criteria that will allow us to determine the degree 
of malignancy and predict the course of BC.
One of the vital problems in experimental and 
clinical oncology is to overcome tumor resistance 
to cytostatics. The fact is that no objective criteria, able 
to determine susceptibility of malignancies to antican-
cer drugs and consequences of the treatment both for 
the tumor and the organism, have been found yet [3].
Today it is finally proved that the phenomenon 
of drug resistance is associated with different intra-
cellular mechanisms of genetic and epigenetic na-
ture [4–8]. At the same time, the list of mechanisms 
that indicate resistance of malignant cells to different 
damaging factors is increasing. So, the studies on ex-
perimental models in vivo and in vitro contribute greatly 
to understand the mechanisms, which determine 
therapy resistance of tumor cells [9–12].
In recent years, researchers have focused their 
attention on the fundamental data regarding the impor-
tance of iron in the basic processes of cell activity. Iron 
is essential and indispensable substance that provides 
a diversity of biological functions and reactions in the 
organism and plays a leading role in the pathogenesis 
of several diseases, including cancer [13–15]. There 
are data showing that differences in metabolism pro-
cesses can be observed in drug-sensitive and -resis-
tant tumors [16]. Iron plays an important role in cell 
growth and division through the proteins involved in the 
regulation of iron metabolism, oxygen consumption, 
DNA synthesis and cell death [17]. Today, researchers 
actively test a hypothesis, according to which iron-
regulatory proteins are essential at different stages 
of carcinogenesis, and therefore they can be consi-
dered as potential markers of malignant progression 
and probable targets for anticancer therapy. According 
to the published results, hepcidin (Hepc) plays one 
of the main roles among such proteins [18].
According to the data of numerous studies, 
changes in Hepc expression are observed in a vari-
ety of malignant tumors [19–21]. It is shown that the 
increase of Hepc expression in tumor cells correlates 
with malignant tumors aggressiveness and low pa-
tient survival rates [22, 23]. By contrast, the decrease 
of Hepc expression inhibits BC progression by reducing 
of intracellular iron quantity. Circulating Hepc, which 
is secreted by liver, has a strong influence on ferropor-
tin-mediated export of iron from the tumor cells. Hepc 
deficiency increases the outflow of iron from tumor 
cells and results in repression of tumor growth [24].
Despite the availability of some data on the features 
of Hepc expression, little is known about Hepc partici-
pation in the development of drug-resistant phenotype 
in malignant tumors. Therefore, there is a need to study 
Hepc participation in the mechanisms of doxorubicin 
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(Dox) resistance in order to develop a strategy for 
overcoming this phenomenon.
MATERIALS AND METHODS
Cell lines and drug treatment. The studies were 
performed in vitro on 6 human BC cell lines: T47D — 
metastatic breast ductal carcinoma; MDA-MB-231 and 
MDA-MB-468 — metastatic breast adenocarcinoma; 
MCF-7 — invasive breast ductal carcinoma, MCF-7/
CP, MCF-7/Dox — its variants, resistant to cisplatin 
(CP) or Dox, respectively.
T47D cells were cultured in RPMI-1640 medium (Sig-
ma, USA) supplemented by bovine insulin (0.2 U/ml) 
and 10% fetal bovine serum (FBS). MCF-7 cells were 
grown in DMEM (Sigma) supplemented by recombi-
nant human insulin (0.01 mg/ml) and 10% FBS. MDA-
MB-231 and MDA-MB-468 cells were cultured in Lei-
bovitz’s L-15 medium (Sigma) supplemented by 10% 
FBS. All cultures were grown on glass cover slips 
in humidified atmosphere with 5% CO2 at 37 °C. The cell 
lines were obtained from the Bank of Cell Lines from 
Human and Animal Tissue of the R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobio-
logy (IEPOR) of the National Academy of Sciences 
(NAS) of Ukraine.
The degree of cell malignancy was evaluated by the 
following criteria: receptor status, proliferation activity, 
adhesive and invasive properties [25]. MDA-MB-231, 
MDA-MB-468, MCF-7/CP and MCF-7/Dox cells 
were considered highly malignant because they did 
not contain steroid hormone receptors, showed high 
invasive potential and low adhesive properties. T47D 
and MCF-7 cells were considered as ones with low de-
gree of malignancy due to high expression of estrogen 
and progesterone receptors, as well as high adhesive 
properties due to increased E-cadherin expression and 
low expression of both N-cadherin and CD44.
The resistant variants MCF-7/Dox and MCF-7/
CP were originated by growing parental MCF-7 cells 
with rising concentrations of CP (from 0.01 to 6 μg/ml) 
or Dox (from 0.1 to 32 μg/ml), respectively. CP and 
Dox were added twice a week after reseeding. Every 
2 months, cell survival rate was analyzed by MTT 
assay. IC50 values for MCF-7 and MCF-7/CP cells 
were 0.25 and 1 μg/ml of CP, respectively, and for 
MCF-7 and MCF-7/Dox cells — 0.5 and 8 μg/ml of Dox, 
respectively. Therefore, MCF-7/CP were 4 times 
as much resistant to the cytotoxic effect of CP and 
MCF-7/DOX cells were 16 times as much resistant 
to the cytotoxic effect of Dox as parental MCF-7 cells.
Immunocytochemical assay. The cells were fixed 
on cover slips (in triplicate for each sample) in ice-cold 
methanol:acetone (1:1) at −20 °C for 120 min and 
incubated with 1% bovine serum albumin solution 
for 20 min. For immunocytochemical assay, primary 
аnti-Hepc monoclonal antibody (1:150) (Abcam, USA). 
UltraVision LP Detection System (Lab Vision, Thermo 
Scientific, USA) and DAB Quanto (Thermo Scientific) 
were used according to the instructions of the manu-
facturers. When immunocytochemical reaction was 
completed, the cells were stained with haematoxylin 
by Mayer and placed in Faramount Aqueous Mounting 
Medium (DakoCytomation, Denmark). Results were 
analyzed by light microscopy (× 1000, oil immersion) 
with the use of classical H-Score method:
S = 1 • N1+ + 2 • N2+ + 3 • N3+,
where S — “H-Score” index, N1+, N2+ and N3+ — 
number of cells with low, medium or high marker ex-
pression [26]. The level of studied markers expression 
was assigned as follows: low — from 0 to 100 H-score 
points, medium — from 100 to 200 H-score points, and 
high — from 200 to 300 H-score points.
Low-temperature Fe(III) electron paramag-
netic resonance (EPR). After 24 h of cultivating, 
the cells were scrapped, washed in PBS, centrifuged 
at 1000 g for 10 min at 4 °C and then the pellet was 
resuspended in PBS. The suspension containing 
2•106 cells was transferred into EPR tubes and im-
mediately frozen in liquid nitrogen. The level of “free” 
iron was determined by a low-temperature EPR 
method [27]. Briefly, samples were maintained at 
−196 °C during recording of the spectra using a finger 
Dewar filled with liquid nitrogen. The following parame-
ters were used for the low-temperature EPR: sweep 
width 1525 G; frequency 9.15 GHz; microwave power 
40 mW; modulation amplitude 10.0 G and modulation 
frequency 100 kHz. The g-value was calculated using 
the standard formula:
g = hv/βH,
where h — Planck’s constant; v — frequency; 
β — Bohr magneton; H — external magnetic field 
at resonance.
Animals and experimental model. The study was 
performed on female rats (120–150 g weight) bred 
in the vivarium of the R.E. Kavetsky IEPOR of the NAS 
of Ukraine (Kyiv, Ukraine). Walker-256 carcinosarcoma 
was chosen as experimental model. The use and care 
of the experimental animals have been performed 
in accordance with the standard international rules 
of biologic ethics and was approved by Institutional 
Animal Care and Use Committee.
Tumor transplantation was performed by subcu-
taneous injection of Walker-256 carcinosarcoma cell 
suspension (2•106 cells/animal) in the thigh area. 
Animals were divided into control (No. 1) and experi-
mental (No. 2) groups (nor less than 10 animals per 
group). When the volume of tumor reached 0.5 cm3, 
five Dox (Ebewe, Austria) injections (1.5 mg/kg daily) 
were administered to the animals of the group No. 2. 
Then the animals were decapitated under narcosis 
(Sedazin, Biowet-Pulawy, Poland) according to the 
rules of Ethic Committee; tumors were resected, tu-
mor cell suspension was prepared and transplanted 
to the animals from the new control and experimental 
groups. Then Dox therapy was performed by the same 
schedule. In total, 12 courses of tumor transplantation/
Dox therapy were performed.
All studies have been performed during develop-
ment of resistance of Walker-256 carcinosarcoma 
to Dox. Animals, which underwent removal of tumor for 
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the study, have not received cytostatic drug directly. 
The Hepc level and “free” iron complexes of parental 
Walker-256 carcinosarcoma (inhibition of growth 
by Dox has was 65.0 ± 5.8%) and resistant variants 
of this tumor (inhibition of growth has — 30.0 ± 2.7% 
and 2.1 ± 0.5%, respectively) have been studied. 
According with the aim of study, changes in the level 
of Hepc in blood of animals was determined in different 
periods of Walker-256 carcinosarcoma growth — 2, 5, 
8 and 14 days after tumor transplantation. According 
to kinetics of tumor growth, the 2nd–5th days are con-
sidered as latent growth period, the 6th–10th days are 
referred to as the phase of exponential growth, and 
the 14th day — as the beginning of the terminal phase 
of tumor growth [28].
The content of Hepc in blood serum and tumor tis-
sue of experimental animals was measured. In blood 
and tumors of these animals, “free” iron complexes 
were determined [29]. Mentioned above indices in tu-
mor were studied on 5th, 8th and 14th days after tumor 
transplantation, exactly.
Evaluation of Hepc content in blood serum and 
tumor homogenates of rats with Walker-256 car-
cinosarcoma by immunoenzyme method. Content 
of Hepc in blood serum and tumor homogenate was 
determined by ELISA using appropriate kits of reagents 
(ELISA Kit for Hepcidin, USA) with use of automatic 
biochemical and immunoenzyme analyzer Chem Well 
2990 (GBG, USA). Samples of blood serum for ELISA 
were obtained in accordance with the recommenda-
tions indicated in instructions to the kits. All samples 
of blood serum had no signs of hemolysis. Homo-
genate of tumor tissue was obtained in PBS solution 
in the ratio of 1:3.
Statistical analysis. STATISTIСA 6.0 computer 
program (StatSoft Inc., USA) was used for statisti-
cal processing of the obtained results. Differences 
between the average values were compared with use 
of Student’s t-test; correlation analysis was performed 
using Pearson correlation coefficient. Differences were 
considered as significant with the probability not less 
than 95% (р < 0.05).
RESULTS AND DISCUSSION
At the first stage of our study, we analyzed the 
features of Hepc expression in cells with different 
degree of malignancy and sensitivity to cytostatics 
(Table). The level of Hepc expression in tested cell lines 
varied. The lowest rate of Hepc expression (less than 
136 H-score points) was observed in the cell lines with 
low-grade malignancy (MCF-7 and T47D). These lines 
were characterized by low invasive activity, which ac-
cording to their molecular phenotype, was determined 
by increased adhesive properties of these cells due 
to high E-cadherin expression, low CD44 expression, 
and the absence of CD24 expression [25]. Indices 
of N-cadherin expression in the cells with low-grade 
malignancy were moderate.
Table. Features of Hepc expression in BC cells with various degrees 
of malignancy and sensitivity to cytostatics
Cell line and degree of malignancy Expression of Hepc, H-score (M ± m) points
T47D, low (n = 3) 97.0 ± 1.3
MCF-7, low (n = 3) 136.0 ± 3.1
MDA-MB-231, high (n = 3) 246.0 ±1.9
MDA-MB-468, high (n = 3) 311.0 ± 2.6
MCF-7/CP, high (n = 3) 220.0 ± 2.8
MCF-7/Dox, high (n = 3) 207.0 ± 1.7
High Hepc expression (≥ 200 H-Score points) was 
observed in the cells with high degree of malignancy 
(MDA-MB-231, MDA-MB-468). In contrast to T47D 
and MCF-7 cell lines with low invasive potential, these 
cells had the highest rate of invasive activity, which 
was determined by significantly higher expression 
of CD44 and CD24 adhesion molecules.
In addition, we evaluated the features of Hepc 
expression in two drug-resistant BC cell lines such 
as MCF-7/CP and MCF-7/Dox (see Table).  According 
to the results of these studies, Hepc expression in MCF-
7/CP and MCF-7/Dox cell lines was much higher than 
in cells with low-grade malignancy. It should be men-
tioned that the rates of invasiveness in both resistant 
cell lines were similar to the rates in cells with high 
degree of malignancy. Both drug-resistant cell lines 
demonstrated low rates of E-cadherin expression, 
high rates of CD44 and N-cadherin expression, and 
the absence of CD24 [25]. So, the in vitro studies 
demonstrated that the increase in Hepc expression 
level is associated with a high degree of malignancy 
and the absence of sensitivity of human BC cells 
to CP and Dox.
Resistance to anticancer therapy is one of the vital 
problems in the modern oncology. Primarily, this is due 
to the fact that today there is no comprehensive data 
on all the rearrangements, which occur in tumor and 
tumor-bearing organism during the development of re-
sistance. Despite the availability of some information 
about the features of Hepc expression in malignant 
processes, there are no published findings regarding 
Hepc participation in the formation of a malignant 
phenotype of cells, which are resistant to cytostatics. 
Also, there are no data regarding the changes in iron 
homeostasis in tumor and in the organism during the 
growth and progression of drug-sensitive and -resis-
tant strains of malignant neoplasms. That is why, at the 
second stage of the research we studied levels of 
“free” iron and Hepc in tumor and organism during the 
formation of resistance to Dox in dynamics of growth 
of sensitive and resistant Walker-256 carcinosarcoma.
We studied these parameters in tumor cells 
of sensitive and resistant Walker-256 carcinosarcoma 
 starting from the 5th day after tumor transplantation 
(end of latent period). As seen from the data presented 
in Fig. 1, the development of drug-resistant phenotype 
in Walker-256 carcinosarcoma cells was accompanied 
by increasing of Hepc and “free” iron content (2.4 and 
1.2 times, respectively).
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Fig. 1. Changes of Hepc (a) and “free” iron (b) levels in tumor 
cells during development of resistance to Dox and the growth 
of sensitive (Walker-256/S) and resistant (Walker-256/Dox) 
Walker-256 carcinosarcoma (n = 10). Note: *p < 0.05 compared 
to the sensitive strain of Walker-256 carcinosarcoma
The study of Hepc levels during the growth of experi-
mental tumors showed that the maximum content of the 
protein in tumor was observed at the exponential phase 
of growth (8th day; Fig. 1) and in blood serum — in termi-
nal phase (14th day; Fig. 2). Reduction of Hepc content 
in tumor tissue at the terminal stage of tumor growth 
(14th day), in our opinion, is explained by the prevalence 
of necrobiotic changes and necrotic processes. This 
proved the fact of intensification of metabolic processes 
associated with a higher Hepc content in the tumor tissue 
of animals with more aggressive tumor phenotype. At the 
same time, we found out that the growth and progression 
of sensitive and resistant Walker-256 carcinosarcoma 
is accompanied by significant increase in the level of 
“free” iron in tumor cells (see Fig. 1). Thus, during the 
exponential and terminal phases of growth, the level 
of “free” iron in the cells of both strains is, respectively, 
3 and 9 times higher than during the latent phase. 
The established fact corresponds to the known data 
about iron as a key element for cell proliferation and 
growth [30]. So, in our study we found out that changes 
of Hepc and “free” iron levels in tumor cells during 
growth of sensitive and resistant Walker-256 carcino-
sarcoma are of identical nature. 
The analysis of the studied parameters in the or-
ganism showed some changes in the Hepc and “free” 
iron content in the serum of animals with drug-sensitive 
and -resistant tumor (Fig. 2). We found that the growth 
of sensitive and resistant Walker-256 carcinosarcoma 
is accompanied by same changes in the content of 
“free” iron levels in serum of experimental animals.
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Fig. 2. Content of Hepc (a) and “free” iron (b) complexes in se-
rum of animals during the growth of sensitive (Walker-256/S) 
and resistant (Walker-256/Dox) Walker-256 carcinosarcoma
There was increase in Hepc level in the serum 
while its maximum level was observed in terminal 
phases of tumor growth (14 days after tumor trans-
plantation). It should be noted that Hepc level in the 
blood of animals with resistant strains increased 
more rapidly compared to the animals with sensitive 
Walker-256 carcinosarcoma. These differences can 
probably be explained by the increased requirement 
of drug-resistant tumor cells in Hepc.
So, the development of resistance to Dox in vivo 
was accompanied by changes in “free” iron and 
Hepc levels in tumor and organism of tumor-bearing 
animals. These changes of studied parameters de-
pended on the growth phase of experimental tumors. 
Our findings suggested that there were some cor-
relations between Hepc expression and such indices 
of BC malignancy as receptor status, adhesive and 
invasive properties of cells. In particular, Hepc expres-
sion depended on the invasion level of BC cells with low 
and high degree of malignancy. According to results 
of numerous studies about Hepc participation in iron 
metabolism and the role of iron in the division and 
growth of cells [13, 14, 31–33] our findings indicated 
a direct role of Hepc in formation of malignant pheno-
type and resistance of cells to drug treatment.
In addition, our study demonstrated the same 
character of changes in the levels of “free” iron 
and Hepc in tumor and host during the growth 
of sensitive and resistant Walker-256 carcinosarcoma. 
We showed that the development of resistance to Dox 
in  Walker-256 carcinosarcoma in vivo was accompa-
nied by increase of Hepc and “free” iron levels. These 
facts coincide with the available data [33–35] and 
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confirm the importance of Hepc in iron metabolism 
in tumor cells for development of drug resistance and 
progression. So, both in vitro and in vivo we proved 
that Hepc is involved in development of a malignant 
phenotype of BC cells and their drug resistance to cy-
tostatic drugs. The obtained data extend the existing 
knowledge about the role of Hepc in BC progression 
highlighting the importance of further studies on Hepc 
relevance in cancer progression and prognosis.
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